Top News
Kolon Group’s Biotech Bet Faces Uncertainty as October Trial Readout Becomes...
Kolon TissueGene's TG-C osteoarthritis treatment failed its first U.S. Phase 3 trial, raising doubts about the biotech's future.
- Our Sponsors Ad -